<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01444196</url>
  </required_header>
  <id_info>
    <org_study_id>2008-005746-22</org_study_id>
    <secondary_id>2008-005746-22</secondary_id>
    <nct_id>NCT01444196</nct_id>
  </id_info>
  <brief_title>Desloratadine 5, 10 and 20mg in Patients With Cold Urticaria</brief_title>
  <acronym>AECUDATT</acronym>
  <official_title>Multi-center, Double Blind, Dose Escalating Study to Compare the Effects of 5 mg, 10mg and 20mg of Desloratadine in Patients With Acquired Cold Urticaria (ACU)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marcus Maurer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the dosis of DL which is sufficient to
      inhibit cold urticaria symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 30 patients (male and female) with ACU will be included in this study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CTTs and CSTTs assessed by TEMPtest 3.0 + urticaria network SOPs</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of wheal(s) at 4°C Intensity of pruritus and burning Number and duration of angioedemas QoL as assessed by DLQI Severity of ACU (by ACUSI)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Urticaria</condition>
  <arm_group>
    <arm_group_label>Desloratadine dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study group: 5 mg Desloratadine during the whole study
Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose of Desloratadine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Study group: 5 mg Desloratadine during the whole study
Study group: 5 mg every day for 14 (+-2 days) start with Visit 2, 10 mg every day for 14 (+-2 days) start with Visit 3, 20 mg every day for 14 (+-2 days) start with Visit 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desloratadine</intervention_name>
    <description>Every day,per mouth,in the evening, for 14 +- 2 days.</description>
    <arm_group_label>Desloratadine dose</arm_group_label>
    <arm_group_label>Dose of Desloratadine</arm_group_label>
    <other_name>No arm names.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent signed and dated

          -  Reliable method of contraception for both women of childbearing potential as well as
             man during the study and 3 months thereafter. A highly effective method of birth
             control is defined as those which result in a low failure rate (i.e. less than 1% per
             year) when used consistently and correctly such as implants, injectables, combined
             oral contraceptives, some IUDs, sexual abstinence or vasectomised partner

          -  Outpatients with ACU for more than 6 weeks. Urticaria symptoms must comprise wheal and
             itch.

          -  Age between 18 and 75 years

        Exclusion Criteria:

          -  Subjects who are inmates of psychiatric wards, prisons, or other state institutions.
             Existing or planned placement in an institution after ruling according to § 40 passage
             1 number 4 AMG (Arzneimittelgesetz).

          -  The presence of permanent severe diseases, especially those affecting the immune
             system, except urticaria and cold urticaria

          -  The presence of permanent gastrointestinal condition which may influence the oral
             therapy (chronic diarrhoea diseases, congenital malformations or surgical mutilations
             of gastrointestinal tract)

          -  History or presence of epilepsy, significant neurological disorders, cerebrovascular
             attacks or ischemia

          -  History or presence of myocardial infarction or cardiac arrhythmia which requires drug
             therapy

          -  Evidence of severe renal dysfunction

          -  Evidence of significant hepatic disease (liver enzymes twice the upper reference
             value)

          -  History of adverse reactions to DL

          -  Presence of active cancer which requires chemotherapy or radiation therapy

          -  Presence of alcohol abuse or drug addiction

          -  Intake of oral corticosteroids within 14 days prior to screening visit

          -  Use of depot corticosteroids or chronic systemic corticosteroids within 21 days prior
             to screening visit

          -  Use of systemic immunosupressants/immunomodulators like ciclosporine A, dapsone,
             methotrexate, mycophenolate, chloroquine, and comparable drugs within 28 days prior to
             screening visit.

          -  Pregnancy or breast-feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Maurer, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite, University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Dermatology, Venerology and Allergology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://urtikaria.net</url>
    <description>Kälteurtikaria</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2011</study_first_submitted>
  <study_first_submitted_qc>September 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2011</study_first_posted>
  <last_update_submitted>September 30, 2011</last_update_submitted>
  <last_update_submitted_qc>September 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Marcus Maurer</investigator_full_name>
    <investigator_title>Head of Research Dept. of Dermatology</investigator_title>
  </responsible_party>
  <keyword>ACU</keyword>
  <keyword>acquired cold urticaria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urticaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Loratadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

